UBS raises Western Midstream stock price target on strong EBITDA

UBS raised its Western Midstream Partners (WES) price target to $48 from $45 (Neutral rating), near the stock’s $48.01 52-week high, even as shares trade around $44.88. UBS projects Q2 2026 EBITDA of $715M vs $683M in Q1 2026, with free cash flow of $363M vs $242M, supported by stronger commodity pricing and the early close of the Brazos acquisition (offset by curtailments/shut-ins). The article also cites an earnings beat in Q1 2026 (EPS $0.85 vs $0.75; revenue $1.12B vs $1.03B) and a $1.6B Brazos Delaware II acquisition, reinforcing an upside/bullish re-rating setup.

Analysis

WES looks more interesting as a quality-of-cash-flow story than as a pure oil beta trade. The market is likely underappreciating that the acquisition plus incremental water-handling capacity can lift fee-based earnings even if commodity prices mean-revert; that makes the upside less dependent on the spot move and more dependent on basin volumes and integration execution. In the near term, the stock can still grind higher because it sits close to the prior high, but the cleaner setup is a rerating on sustained free-cash-flow visibility, not just analyst target resets.

The second-order winner set is actually the producer base in the Delaware: COP, CVX, DVN, and XOM benefit if WES’s expanded infrastructure reduces bottlenecks and raises takeaway/produced-water flexibility. That can improve producer realized pricing and operating cadence, but it also makes WES more strategically embedded, which can support longer-duration contracts and lower churn. If the water-treatment pilot scales, the equity could start trading less like a midstream commodity proxy and more like a scarce regional infrastructure asset.

Risk is that the market is confusing near-term commodity support with durable earnings power. A move back below the mid-$50s crude threshold would quickly expose the leverage to basin activity and curtailments; that’s the main falsifier over the next 1-3 months. Over 6-18 months, the thesis breaks if management cannot convert the Brazos step-up into visible distribution growth or buybacks, because then the stock is left with multiple compression risk near its highs rather than a true fundamental re-rating.

Key Decisions for Investors

• Long WES on pullbacks into the mid-$44s with a 1-3 month target toward $48-51; stop if crude falls back below $57 or if next quarter guidance trims FCF/EBITDA.
• Pair trade: long WES / short DVN for 1-3 months to express lower commodity beta and better fee-based cash-flow visibility; thesis breaks if crude re-accelerates above recent highs and producer leverage outperforms.
• If you want broader hedge, go long WES / short XOP into energy volatility; WES should outlast a commodity mean-reversion because its upside is more infrastructure-driven than price-driven.
• Alert, not a trade yet: watch the next quarter’s volume and produced-water commentary. If management shows that Brazos integration is lifting FCF without raising maintenance capex materially, the stock can justify a move above the current target range.